Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 16/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25089766 | 0.85 | P2RX7 (0.46) | P2RX7SLC6A2SLC6A4CTSSCTSK | |
| SCHEMBL10540791 | 0.82 | P2RX7 (0.46) | P2RX7SLC6A2SLC6A4 | |
| SCHEMBL10747351 | 0.82 | P2RX7 (0.46) | P2RX7SLC6A2SLC6A4 | |
| SCHEMBL24008327 | 0.82 | GABRA1 (0.46) | P2RX7GABRA1GABRB2 | |
| SCHEMBL1635491 | 0.82 | PNMT (0.54) | P2RX7SLC6A2SLC6A4 | |
| SCHEMBL27176597 | 0.80 | GABRA1 (0.42) | P2RX7GABRA1GABRB2 | |
| SCHEMBL29129467 | 0.80 | P2RX7 (0.44) | P2RX7SLC6A2SLC6A4 | |
| SCHEMBL3283101 | 0.80 | P2RX7 (0.44) | P2RX7SLC6A2SLC6A4 | |
| SCHEMBL4557992 | 0.80 | P2RX7 (0.44) | P2RX7SLC6A2SLC6A4 | |
| SCHEMBL488470 | 0.80 | P2RX7 (0.53) | P2RX7SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661921-B1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NODTHERA LTD (GB) | 2023-10-18 | — | — | EP | disclosed |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| WO-2021000933-A1 | PYRIMIDINONE COMPOUNDS AS CHYMASE INHIBITORS AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-01-07 | — | — | WO | disclosed |
| EP-3091970-B1 | LXR AGONISTS AND USES THEREOF | RGENIX INC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-10-24 | — | — | US | disclosed |
| US-20170216283-A1 | COMPOUNDS AND USES | ASTRAZENECA AB (SE) | 2017-08-03 | — | — | US | disclosed |
| US-20170216283-A1 | COMPOUNDS AND USES | ASTRAZENECA AB (SE) | 2017-08-03 | — | — | US | disclosed |
| US-9657001-B2 | Compounds and uses | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| US-9657001-B2 | Compounds and uses | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| US-20160326143-A1 | COMPOUNDS AND USES | ASTRAZENECA AB (SE) | 2016-11-10 | — | — | US | disclosed |
| WO-2011021645-A1 | BICYCLIC UREA DERIVATIVE OR PHARMACOLOGICALLY PERMITTED SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2011-02-24 | — | — | WO | disclosed |
| EP-1749001-B1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMA INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-7524841-B2 | 4,4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7524841-B2 | 4,4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216283-A1 | COMPOUNDS AND USES | LTC4S, LTB4R2, LTA4H | P2RX7 2324/4885GABRA1 3365/4885GABRB2 4109/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | P2RX7 741/4885GABRA1 1141/4885GABRB2 2290/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | P2RX7 790/4885GABRA1 933/4885GABRB2 1739/4885 |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | DRD3, DRD2, DRD4 | P2RX7 281/4885GABRA1 159/4885GABRB2 313/4885 |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | P2RX7 3611/4885GABRA1 2064/4885GABRB2 3462/4885 |
| US-20160326143-A1 | COMPOUNDS AND USES | LTC4S, LTB4R2, LTA4H | P2RX7 2324/4885GABRA1 3365/4885GABRB2 4109/4885 |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | P2RX7 3611/4885GABRA1 2064/4885GABRB2 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.